Used in the treatment of chronic myeloid leukemia (CML), particularly in patients who have developed resistance or intolerance to other tyrosine kinase inhibitors. It functions as a selective allosteric inhibitor of the BCR-ABL1 fusion protein, effectively targeting the abnormal kinase responsible for CML progression. Due to its unique mechanism of action, it offers a therapeutic option for cases with specific mutations, including the T315I mutation, which are often resistant to conventional therapies. Currently investigated in both chronic and accelerated phases of CML, asciminib provides a targeted approach with potentially fewer off-target side effects compared to earlier kinase inhibitors.